Figure 6. Effect of the combination of chemotherapy and TA-CIN vaccination on the anti-tumor effect, HPV16 E7-specific CD8+ T cell and L2-specific neutralizing antibody responses in TC-1 tumor bearing mice.

A. Briefly, 5∼8 weeks old C57BL/6 mice (5–9 mice per group) were injected with 1×10⁵ of TC-1 tumor cells subcutaneously. The tumor-bearing mice were divided into 6 groups; one untreated, and 5 other groups were given 5 mg/kg of cisplatin (Cis) via intraperitoneal injection on day 5 and 12. Of the 5 groups that were treated with cisplatin, one was not vaccinated (Cisplatin) and another received intratumoral GPI-0100 alone (Cis+GPI-0100 IT), another was vaccinated intratumorally with 6.25 µg/mouse TA-CIN alone in 20 µL (Cis+TA-CIN IT), and the last two groups were given 6.25 µg/mouse TA-CIN formulated with 50 µg of GPI-0100 in 20 µL mannitol solution (frozen/thawed once) via intramuscular injection (Cis+TA-CIN+GPI-0100 I.M.) or via intratumor injection (Cis+TA-CIN+GPI-0100 I.T.). In all groups, the vaccinations were given on days 6, 13 and 20. An illustrative schema is shown in S7 Fig. A. Summary of the TC-1 tumor growth volume. B. Kaplan and Meier survival analysis of TC-1 tumor cell challenged mice treated with the different regimens. C. Summary of flow cytometry analysis of HPV16 E7-specific CD8⁺ T cell responses analyzed by HPV16 E7 tetramer staining. The data were acquired with FACSCalibur and analyzed with CellQuest (and representative data is shown in S8 Fig.). D. Summary of HPV16 neutralizing antibody titer analyzed with HPV16-SEAP pseudovirus based neutralization assay.